Backing 29 domestic firms along with KOTRA
[by Yu, Suin] The 바카라사이트 온카판 Biotechnology Industry Organization (바카라사이트 온카판BIO) announced on June 10 that it has organized a large-scale 바카라사이트 온카판n pavilion at the 'BIO International Convention 2025 (BIO USA),' the world's largest biotechnology industry exhibition, scheduled to take place in Boston, USA, from June 16 to 19 for four days (local time). The 바카라사이트 온카판BIO and KOTRA will jointly operate the '바카라사이트 온카판 Pavilion,' covering an area of 6,000 square feet, to support the global expansion of 29 바카라사이트 온카판n companies and organizations.
The Korea Pavilion, operated for the 22nd consecutive year, has reached its largest scale yet in terms of both the number of participating companies and the exhibition area, surpassing last year’s figures. It plans to bolster global partnering results for Korean companies by strengthening customized partnering initiatives and on-site promotional activities.
The 바카라사이트 온카판 Pavilion exhibition will showcase companies representing the full spectrum of the biotechnology industry, including contract manufacturing (CMO) and clinical services, small and medium-sized businesses (materials, parts, and equipment), novel drug development, and platform technologies. In total, 51 companies will participate, comprising 26 companies chosen by the KoreBIO and KOTRA through a government-supported selection process and 25 companies selected by three organizations: Seoul Biohub, Chuncheon Bioindustry Foundation, and the 바카라사이트 온카판 Planning & Evaluation Institute of Industrial Technology (KEIT).
Notably, the partnering consultation center, which had previously operated in an open format, was partially closed to better meet the specific needs of participating companies. In addition to the exhibition promotion booth, an IR pitching stage will be set up to maximize the promotional impact of participating companies, while support for international network expansion and investment meetings will be maximized.
In addition to managing the Korean Pavilion, KoreaBIO will also participate as a representative of Korea in the official meetings and conference panels at this year’s BIO USA event. On June 15 (local time), the KoreaBIO plans to attend the closed-door general meeting of the 'International Council of Biotechnology Associations (ICBA),' where biotech association officials from around the world discuss the status of the biotechnology industry in each country and identify cooperative opportunities. At the council, KoreaBIO aims to share major issues related to the Korean biotechnology industry and highlight the importance of international cooperation. Key topics will include the domestic impact of the new U.S. government's bio-industry policies, cooperation tasks for stabilizing the global biopharmaceutical supply chain, and the current status of Korea’s biotech industry.
Then, on June 18, during the main event afternoon conference session titled 'Building Resilient Global and National Supply Chains,' Hwang Ju-ri, Head of Exchange and Cooperation Headquarters at the 바카라사이트 온카판BIO, will participate as a representative panelist for 바카라사이트 온카판. She will discuss strategies and international cooperation efforts aimed at securing stable supply chains in each country that have become increasingly vulnerable due to recent geopolitical tensions and climate change.
The 바카라사이트 온카판BIO will also organize a side event representing 바카라사이트 온카판. The event, '바카라사이트 온카판 BioTech Partnership (KBTP) @ BIO 2025,' will take place from 6 p.m. on June 17, the second day of the convention. It will be co-hosted by the 바카라사이트 온카판BIO, KOTRA, the 바카라사이트 온카판 Planning & Evaluation Institute of Industrial Technology (KEIT), the 바카라사이트 온카판 Exchange, Invest Seoul, and Gyeonggido Business & Science Accelerator (GBSA). The event will serve as a networking event that provides the opportunity to foster cooperation with international investors and companies.
The KBTP event is structured into two parts: Part 1 (Korea Capital Market Spotlight) and Part 2 (Meet the Korean Biotechs). In Part 1, speakers will present Korea’s strategies for attracting international companies, guidelines for listing on KOSDAQ, and procedures for entering the Korean market to overseas biotech firms and investors. The session will feature speakers from Invest Seoul, the Korea Exchange, Korea Investment Partners, Samsung Securities, Bae, Kim & Lee Law Firm, and Samil PwC Accountings, who will share practical entry strategies and insights into Korea’s investment and listing environment.
During the networking session of Part 2, ABL Bio, which has signed technology transfer agreements with global pharmaceutical companies like Sanofi and GlaxoSmithKline (GSK), will deliver the first presentation. Following this, Yuhan Corporation, which secured a technology transfer deal worth around KRW 1.6 trillion (approximately USD 1.1 billion) with a Johnson & Johnson (J&J) subsidiary and has received novel drug approval from the U.S. Food and Drug Administration (FDA), will participate as a speaker to share its know-how on global cooperation. The presentation will highlight strategies for Korean biotech companies entering the global market and key partnership examples. In particular, the Head of Asia Partnering at Roche, a multinational pharmaceutical company, will also speak, discussing cases of collaboration with Asian and Korean biotech companies and emphasizing the global potential and competitiveness of Korea’s bio industry.
This year’s KBTP event will bring together not only promising biotech companies but also government officials, representatives from global pharmaceutical companies, venture capitalists (VCs), and other key players who shape the global bio ecosystem, fostering extensive networking opportunities. Pre-registration for the event is available through the KoreaBIO’s official website.
“This year, through BIO USA, we will fully support domestic biotech companies by mobilizing every available resource to promote their technologies and facilitate collaboration and exchange with international markets,” stated Hwang Ju-ri, Head of Exchange and Cooperation Headquarters at the KoreaBIO. “We will definitely demonstrate the competitive strength of the Korean bio industry in the global arena,” she added.